GeoVax Labs, Inc. (Nasdaq: GOVX) has identified 2026 as a pivotal inflection year, driven by multiple late-stage clinical, regulatory, and manufacturing milestones across its diversified portfolio of vaccines and immunotherapies. The company provided this outlook following engagements during the J.P. Morgan Healthcare Conference Week in San Francisco, where it outlined execution priorities and value creation opportunities.
“GeoVax enters 2026 with increasing clarity on execution, prioritization, and value creation,” said David Dodd, Chairman & CEO of GeoVax. “With GEO-MVA representing an expedited path to potential commercialization, alongside multiple clinical data readouts relative to GEO-CM04S1, our multi-antigen COVID-19 vaccine and, the anticipated initiation of the Phase 2 Gedeptin trial, we believe that this year will provide a meaningful convergence of regulatory, clinical, and manufacturing catalysts for the Company.”
The company’s most advanced program, GEO-MVA, targets Mpox and smallpox in a market constrained by reliance on a single foreign manufacturer with insufficient production capacity. Following supportive Scientific Advice from the European Medicines Agency (EMA), GeoVax has regulatory alignment on a single, pivotal Phase 3 immunobridging study versus the approved MVA vaccine, de-risking the regulatory pathway. Key 2026 milestones include initiation of the Phase 3 trial expected in the second half of the year, continued engagement with European and global health authorities, and advancement toward a U.S.-sourced vaccine supply model.
In oncology, GeoVax is advancing Gedeptin, a gene-directed enzyme prodrug therapy. Expected 2026 inflection points include publication of results from the recently completed Gedeptin trial and initiation of a Phase 2 study evaluating Gedeptin in combination with an immune checkpoint inhibitor for head and neck cancer by year-end. Updates on preclinical evaluations in combination with checkpoint inhibitors may support expansion into additional solid tumors.
GeoVax’s next-generation COVID-19 vaccine, GEO-CM04S1, is a multi-antigen candidate designed for immunocompromised and high-risk populations. In 2026, the company expects clinical data readouts from ongoing Phase 2 trials, continued evaluation as a primary and booster vaccine in immunocompromised populations, and translational insights to support regulatory and partnering discussions.
The AGE1 continuous avian cell-line manufacturing process is directly integrated into the GEO-MVA program, offering scalability and supply chain resilience. Manufacturing progress in 2026 includes continued optimization for commercial-scale production and advancement as a U.S.-based solution for pandemic preparedness.
“As we emphasized during JP Morgan/Biotech Showcase Week, GeoVax has moved beyond platform validation,” Dodd added. “We are now executing against clearly defined milestones, with GEO-MVA leading the portfolio and multiple additional programs advancing toward value-inflection events in 2026 and beyond.”
For more information, visit www.geovax.com.
